

## B. REMARKS

Kindly amend Page 9, line 18 to Page 10, line 6 of the specification to read as follows:

### Marked-up Version

#### FIGURE 29

Nucleotide (SEQ ID NO:83) and amino acid (SEQ ID NO:84) sequences of the chimeric LO-CD2a V<sub>i</sub> chain.

#### FIGURE 30

Nucleotide (SEQ ID NO:85) and amino acid (SEQ ID NO:86) sequences of the chimeric LO-CD2a V<sub>H</sub> chain.

#### FIGURE 31

Amino acid sequences of the light chain variable region of rat LO-CD2a (SEQ ID NO:87), human HUM5400 (SEQ ID NO:89), and humanized LO-CD2a (SEQ ID NO:88).

#### FIGURE 32

Nucleotide (SEQ ID NO:90) and amino acid (SEQ ID NO:91) sequences of the humanized LO-CD2a variable region.

#### FIGURE 33

Amino acid sequences of the heavy chain variable region of rat LO-CD2a (SEQ ID NO:92), human Amu 5-3 (SEQ ID NO:94), and humanized LO-CD2a (SEQ ID NO:93).

#### FIGURE 34

Nucleotide (SEQ ID NO:95) and amino acid (SEQ ID NO:96) sequences of the humanized LO-CD2a heavy chain variable region.

Kindly amend the first full paragraph of Page 12 as follows:

Marked-up Version

A cell line which produces LO-CD2a, was deposited on July 28, 1993, at the American Type Culture Collection, ~~42301 Parklawn Drive, Rockville, Md. 20852~~ 10801 University Boulevard, Manassas, Va. 20110-2209, and was given the ATCC accession number ATCC HB11423. Such antibody is a rat monoclonal antibody. Because the strain referred to is being maintained under the terms of the Budapest Treaty, it will be made available to a patent office signatory to the Budapest Treaty.

Clean Version

A cell line which produces LO-CD2a, was deposited on July 28, 1993, at the American Type Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209, and was given the ATCC accession number ATCC HB11423. Such antibody is a rat monoclonal antibody. Because the strain referred to is being maintained under the terms of the Budapest Treaty, it will be made available to a patent office signatory to the Budapest Treaty.

**D. REMARKS**

Pages 9, 10, and 12 have been amended in accordance with the Examiner's helpful suggestions.

Claims 30-43 have been cancelled without prejudice. The fact that Claims 30-43 have been cancelled without prejudice is not to be construed as an admission by Applicants or Applicants' attorneys that such claims are not patentable, and Applicants reserve the right to prosecute such claims in a continuing application.


Applicants note that the Examiner has allowed Claim 44.

Claim 45 has been added. Claim 45 depends upon Claim 44. Because Claim 44 has been allowed, Applicants assert that Claim 45 is allowable as well.

Applicants also note that the terminal disclaimers with respect to U.S. Patent No. 5,951,983, and 5,730,939 have been received and accepted.

For the above reasons and others, this application is in condition for allowance, it is therefore respectfully requested that the rejections be reconsidered and withdrawn and a favorable action is hereby solicited.

Respectfully submitted,

  
Raymond J. Lillie  
Registration No. 31,778